– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical- stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the second quarter ended ...